{"title":"Lesch-Nyhan综合征的动物和细胞模型","authors":"Vanna Micheli , Gabriella Jacomelli , Annalisa Santucci , Giulia Bernardini","doi":"10.1016/j.ddmod.2019.10.004","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Lesch–Nyhan Disease (LND) is a rare X-linked recessive metabolic and neurological syndrome due to the deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). Peculiar neurological symptoms occur in LND: </span>dystonia, </span>choreoathetosis, compulsive self-injurious behaviour, with no obvious correlation to the deficiency of this </span>purine<span> salvage anzyme. A dopaminergic<span><span> deficit was found to underlie the neurologic symptoms, but the aetiology for such alteration seemed inexplicable. Several lines of research were carried out to find the molecular basis for the neurological phenotype, and HPRT deficient animal and cellular models were developed. None of them, animal or cellular model, can be considered the completely proper one. Available animal models are rodents, which share several biochemical and molecular abnormalities with HPRT deficient patients, but do not display similar neurologic symptoms. Cellular models obtained from different cell lines present notable biochemical and molecular aberrations though many discrepancies suggest significant differences depending upon cell types and tissue source. Nevertheless, experimental studies on both models provided remarkable information on the biochemical and molecular pathways potentially responsible for the neurological damage in this disease, demonstrating transcriptional aberrations affecting different genes in various metabolic pathways and gene dysregulations in neuronal development and differentiation, producing </span>neurotransmission<span> defects. These findings led to attribute an unexpected paramount role in neurodevelopment to HPRT, beside the well-known metabolic functions.</span></span></span></p></div>","PeriodicalId":39774,"journal":{"name":"Drug Discovery Today: Disease Models","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddmod.2019.10.004","citationCount":"2","resultStr":"{\"title\":\"Animal and cell models for Lesch-Nyhan syndrome\",\"authors\":\"Vanna Micheli , Gabriella Jacomelli , Annalisa Santucci , Giulia Bernardini\",\"doi\":\"10.1016/j.ddmod.2019.10.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>Lesch–Nyhan Disease (LND) is a rare X-linked recessive metabolic and neurological syndrome due to the deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). Peculiar neurological symptoms occur in LND: </span>dystonia, </span>choreoathetosis, compulsive self-injurious behaviour, with no obvious correlation to the deficiency of this </span>purine<span> salvage anzyme. A dopaminergic<span><span> deficit was found to underlie the neurologic symptoms, but the aetiology for such alteration seemed inexplicable. Several lines of research were carried out to find the molecular basis for the neurological phenotype, and HPRT deficient animal and cellular models were developed. None of them, animal or cellular model, can be considered the completely proper one. Available animal models are rodents, which share several biochemical and molecular abnormalities with HPRT deficient patients, but do not display similar neurologic symptoms. Cellular models obtained from different cell lines present notable biochemical and molecular aberrations though many discrepancies suggest significant differences depending upon cell types and tissue source. Nevertheless, experimental studies on both models provided remarkable information on the biochemical and molecular pathways potentially responsible for the neurological damage in this disease, demonstrating transcriptional aberrations affecting different genes in various metabolic pathways and gene dysregulations in neuronal development and differentiation, producing </span>neurotransmission<span> defects. These findings led to attribute an unexpected paramount role in neurodevelopment to HPRT, beside the well-known metabolic functions.</span></span></span></p></div>\",\"PeriodicalId\":39774,\"journal\":{\"name\":\"Drug Discovery Today: Disease Models\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.ddmod.2019.10.004\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Discovery Today: Disease Models\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1740675719300349\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Disease Models","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1740675719300349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
Lesch–Nyhan Disease (LND) is a rare X-linked recessive metabolic and neurological syndrome due to the deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). Peculiar neurological symptoms occur in LND: dystonia, choreoathetosis, compulsive self-injurious behaviour, with no obvious correlation to the deficiency of this purine salvage anzyme. A dopaminergic deficit was found to underlie the neurologic symptoms, but the aetiology for such alteration seemed inexplicable. Several lines of research were carried out to find the molecular basis for the neurological phenotype, and HPRT deficient animal and cellular models were developed. None of them, animal or cellular model, can be considered the completely proper one. Available animal models are rodents, which share several biochemical and molecular abnormalities with HPRT deficient patients, but do not display similar neurologic symptoms. Cellular models obtained from different cell lines present notable biochemical and molecular aberrations though many discrepancies suggest significant differences depending upon cell types and tissue source. Nevertheless, experimental studies on both models provided remarkable information on the biochemical and molecular pathways potentially responsible for the neurological damage in this disease, demonstrating transcriptional aberrations affecting different genes in various metabolic pathways and gene dysregulations in neuronal development and differentiation, producing neurotransmission defects. These findings led to attribute an unexpected paramount role in neurodevelopment to HPRT, beside the well-known metabolic functions.
期刊介绍:
Drug Discovery Today: Disease Models discusses the non-human experimental models through which inference is drawn regarding the molecular aetiology and pathogenesis of human disease. It provides critical analysis and evaluation of which models can genuinely inform the research community about the direct process of human disease, those which may have value in basic toxicology, and those which are simply designed for effective expression and raw characterisation.